Microcirculation Inflammation Associates With Outcome in Renal Transplant Patients With De Novo Donor-Specific Antibodies

被引:90
作者
de Kort, H. [1 ]
Willicombe, M. [2 ]
Brookes, P. [3 ]
Dominy, K. M. [1 ]
Santos-Nunez, E. [3 ]
Galliford, J. W. [2 ]
Chan, K. [2 ]
Taube, D. [2 ]
McLean, A. G. [2 ]
Cook, H. T. [1 ]
Roufosse, C. [1 ]
机构
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Histopathol, London, England
[2] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Imperial Coll Kidney & Transplant Ctr, London, England
[3] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Histocompatibil & Immunogenet Lab, London, England
关键词
Antibody-mediated rejection; C4d; donor-specific antibodies; histopathology; microcirculation inflammation; renal transplantation; ACUTE HUMORAL REJECTION; HLA ANTIBODIES; KIDNEY-TRANSPLANT; MEDIATED REJECTION; ALLOGRAFT PATHOLOGY; GRAFT FAILURE; RECIPIENTS; CLASSIFICATION; BIOPSIES;
D O I
10.1111/j.1600-6143.2012.04325.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
In renal transplant patients with de novo donor-specific antibodies (dnDSA) we studied the value of microcirculation inflammation (MI; defined by the addition of glomerulitis (g) and peritubular capillaritis (ptc) scores) to assess long-term graft survival in a retrospective cohort study. Out of all transplant patients with standard immunological risk (n = 638), 79 (12.4%) developed dnDSA and 58/79 (73%) had an indication biopsy at or after dnDSA development. Based on the MI score on that indication biopsy patients were categorized, MI0 (n = 26), MI1?+?2 (n = 21) and MI?=?3 (n = 11). The MI groups did not differ significantly pretransplantation, whereas posttransplantation higher MI scores developed more anti-HLA class I?+?II DSA (p?= 0.011), showed more TCMR (p?<?0.001) and showed a trend to C4d-positive staining (p = 0.059). Four-year graft survival estimates from time of indication biopsy were MI0 96.1%, MI1?+?2 76.1% and MI?=?3 17.1%; resulting in a 24-fold increased risk of graft failure in the MI?=?3 compared to the MI0 group (p = 0.003; 95% CI [3.0196.0]). When adjusted for C4d, MI?=?3 still had a 21-fold increased risk of graft failure (p = 0.005; 95% CI [2.5180.0]), while C4d positivity on indication biopsy lost significance. In renal transplant patients with de novo DSA, microcirculation inflammation, defined by g?+?ptc, associates with graft survival.
引用
收藏
页码:485 / 492
页数:8
相关论文
共 50 条
  • [31] De Novo DQ Donor-Specific Antibodies Are Associated With a Significant Risk of Antibody-Mediated Rejection and Transplant Glomerulopathy
    Willicombe, Michelle
    Brookes, Paul
    Sergeant, Ruhena
    Santos-Nunez, Eva
    Steggar, Corinna
    Galliford, Jack
    Mclean, Adam
    Cook, Terence H.
    Cairns, Tom
    Roufosse, Candice
    Taube, David
    TRANSPLANTATION, 2012, 94 (02) : 172 - 177
  • [32] Below the WaterlineuThe Danger of De Novo Donor-Specific HLA Antibodies
    Kokko, K. E.
    Colvin, R. B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (05) : 1077 - 1078
  • [33] Systematic Screening Using Luminex for De Novo C3d Fixing of Class II Donor-Specific Antibodies is Correlated With Luminex Mean Fluorescence Intensity in Renal Transplant Patients
    Villemaire, Morgane
    Jouve, Thomas
    Bourdin, Anne
    Janbon, Benedicte
    Pinel, Nicole
    Tetaz, Rachel
    Terrier, Nicolas
    Rostaing, Lionel
    Masson, Dominique
    Malvezzi, Paolo
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2019, 17 (04) : 483 - 489
  • [34] Renal allograft rejection, lymphocyte infiltration, and de novo donor-specific antibodies in a novel model of non-adherence to immunosuppressive therapy
    Kuehne, Louisa
    Jung, Bettina
    Poth, Helen
    Schuster, Antonia
    Wurm, Simone
    Ruemmele, Petra
    Banas, Bernhard
    Bergler, Tobias
    BMC IMMUNOLOGY, 2017, 18
  • [35] De Novo Donor-Specific Antibodies after Heart Transplantation: A Comprehensive Guide for Clinicians
    Marco, Irene
    Garcia, Juan Carlos Lopez-Azor
    Martin, Javier Gonzalez
    Sanchez, Andrea Severo
    Carmena, Maria Dolores Garcia-Cosio
    Sierra, Esther Mancebo
    Baguda, Javier de Juan
    Calvo, Javier Castrodeza
    Perez, Francisco Jose Hernandez
    Delgado, Juan Francisco
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (23)
  • [36] Impact of C1q fixing donor-specific antibodies on renal transplant outcome
    Baranwal, Ajay Kumar
    Goswami, Sanjeev
    Agarwal, Sanjay Kumar
    Kaur, Gurvinder
    Mehra, Narinder Kumar
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2021, 94 (01)
  • [37] Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients
    Kim, Hyung Woo
    Lee, Juhan
    Heo, Seok-Jae
    Kim, Beom Seok
    Huh, Kyu Ha
    Yang, Jaeseok
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [38] The detrimental impact of persistent vs an isolated occurrence of de novo donor-specific antibodies on intermediate-term renal transplant outcomes
    Loucks-DeVos, Jennifer M.
    Eagar, Todd N.
    Gaber, A. Osama
    Patel, Samir J.
    Teeter, Larry D.
    Graviss, Edward A.
    Knight, Richard J.
    CLINICAL TRANSPLANTATION, 2017, 31 (08)
  • [39] Donor-specific antibodies development in renal living-donor receptors: Effect of a single cohort
    Andrade-Sierra, Jorge
    Cueto-Manzano, Alfonso M.
    Rojas-Campos, Enrique
    Cardona-Munoz, Ernesto
    Cerrillos-Gutierrez, Jose, I
    Gonzalez-Espinoza, Eduardo
    Evangelista-Carrillo, Luis A.
    Medina-Perez, Miguel
    Jalomo-Martinez, Basilio
    Nieves Hernandez, Juan
    Pazarin-Villasenor, Leonardo
    Mendoza-Cerpa, Claudia A.
    Gomez-Navarro, Benjamin
    Miranda-Diaz, Alejandra G.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2021, 35
  • [40] The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss
    Schinstock, C. A.
    Cosio, F.
    Cheungpasitporn, W.
    Dadhania, D. M.
    Everly, M. J.
    Samaniego-Picota, M. D.
    Cornell, L.
    Stegall, M. D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 (06) : 1574 - 1584